116 related articles for article (PubMed ID: 26155021)
1. Palliative systemic therapy for young women with metastatic breast cancer.
Eng LG; Dawood S; Dent R
Curr Opin Support Palliat Care; 2015 Sep; 9(3):301-7. PubMed ID: 26155021
[TBL] [Abstract][Full Text] [Related]
2. First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer.
Peron J; Tredan O; Ray-Coquard I; Bachelot T; Labidi Galy SI; Favier B; Treilleux I; Guastalla JP
Bull Cancer; 2012 Feb; 99(2):E18-25. PubMed ID: 22257781
[TBL] [Abstract][Full Text] [Related]
3. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
Tan SH; Wolff AC
Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
[TBL] [Abstract][Full Text] [Related]
4. Metastatic breast cancer.
Stevanovic A; Lee P; Wilcken N
Aust Fam Physician; 2006 May; 35(5):309-12. PubMed ID: 16680209
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer.
Damasceno M
Curr Opin Oncol; 2011 Apr; 23 Suppl():S3-9. PubMed ID: 21490481
[TBL] [Abstract][Full Text] [Related]
6. Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer.
Di Lauro L; Vici P; Del Medico P; Laudadio L; Tomao S; Giannarelli D; Pizzuti L; Sergi D; Barba M; Maugeri-Saccà M
Breast Cancer Res Treat; 2013 Aug; 141(1):119-23. PubMed ID: 23982884
[TBL] [Abstract][Full Text] [Related]
7. Endocrine therapy for advanced/metastatic breast cancer.
Schiavon G; Smith IE
Hematol Oncol Clin North Am; 2013 Aug; 27(4):715-36, viii. PubMed ID: 23915741
[TBL] [Abstract][Full Text] [Related]
8. Predictors of Discontinuation of Adjuvant Hormone Therapy in Patients With Breast Cancer.
He W; Fang F; Varnum C; Eriksson M; Hall P; Czene K
J Clin Oncol; 2015 Jul; 33(20):2262-9. PubMed ID: 26033800
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant endocrine therapy in premenopausal women with breast cancer.
González Martín A; de la Cruz S; Márquez R
Breast Cancer Res Treat; 2010 Sep; 123 Suppl 1():43-7. PubMed ID: 20711666
[No Abstract] [Full Text] [Related]
10. Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen.
Ruddy KJ; DeSantis SD; Barry W; Guo H; Block CC; Borges V; Winer EP; Partridge AH
Clin Breast Cancer; 2014 Dec; 14(6):413-6. PubMed ID: 24970714
[TBL] [Abstract][Full Text] [Related]
11. New strategies for managing metastatic breast cancer.
Olin JJ; Muss HB
Oncology (Williston Park); 2000 May; 14(5):629-41; discussion 642-4, 647-8. PubMed ID: 10853456
[TBL] [Abstract][Full Text] [Related]
12. [Progress in second-line therapies for metastatic breast cancer].
Shigekawa T; Osaki A; Saeki T
Gan To Kagaku Ryoho; 2015 Apr; 42(4):408-15. PubMed ID: 25963688
[TBL] [Abstract][Full Text] [Related]
13. An overview of letrozole in postmenopausal women with hormone-responsive breast cancer.
Barnadas A; Estévez LG; Lluch-Hernández A; Rodriguez-Lescure A; Rodriguez-Sanchez C; Sanchez-Rovira P
Adv Ther; 2011 Dec; 28(12):1045-58. PubMed ID: 22068628
[TBL] [Abstract][Full Text] [Related]
14. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
[TBL] [Abstract][Full Text] [Related]
15. Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.
Colozza M; de Azambuja E; Personeni N; Lebrun F; Piccart MJ; Cardoso F
Oncologist; 2007 Mar; 12(3):253-70. PubMed ID: 17405890
[TBL] [Abstract][Full Text] [Related]
16. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
Winer EP; Hudis C; Burstein HJ; Wolff AC; Pritchard KI; Ingle JN; Chlebowski RT; Gelber R; Edge SB; Gralow J; Cobleigh MA; Mamounas EP; Goldstein LJ; Whelan TJ; Powles TJ; Bryant J; Perkins C; Perotti J; Braun S; Langer AS; Browman GP; Somerfield MR
J Clin Oncol; 2005 Jan; 23(3):619-29. PubMed ID: 15545664
[TBL] [Abstract][Full Text] [Related]
17. A practical overview of aromatase inhibitors in postmenopausal women with hormone receptor-positive breast cancer.
Younus J; Vandenberg TA
Bull Cancer; 2005 Apr; 92(4):E39-44. PubMed ID: 15888383
[TBL] [Abstract][Full Text] [Related]
18. [Aromatase inhibitors in the adjuvant therapy of breast cancer].
Bauerschlag D; Schem C; Maass N; Jonat W
Gynakol Geburtshilfliche Rundsch; 2005 Jun; 45(3):132-6. PubMed ID: 15990437
[TBL] [Abstract][Full Text] [Related]
19. Treatment options in androgen-independent prostate cancer.
Lara PN; Meyers FJ
Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
[TBL] [Abstract][Full Text] [Related]
20. Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities.
Conlin AK; Seidman AD
Clin Breast Cancer; 2008 Jun; 8(3):215-23. PubMed ID: 18650151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]